The glycosphingolipid inhibitor eliglustat inhibits autophagy in osteoclasts to increase bone mass and reduce myeloma bone disease (2021)

First Author: Leng H
Attributed to:  University of Oxford Confidence in Concept – Round 7 funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1101/2021.02.05.429906

Publication URI: http://dx.doi.org/10.1101/2021.02.05.429906

Type: Preprint